Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR with an updated meta-analysis

Funding: This study was funded by Shionogi, B.V.

Competing interests: The authors declare no conflicts of interest beyond being employees of Shionogi.

Ethical approval: Not required.

Sequence information: Not applicable.

Medical writing support: Medical writing support was provided by Nathan Price-Lloyd of Oxford PharmaGenesis, Oxford, UK, and was funded by Shionogi, B.V.

Comments (0)

No login
gif